Giuliano Tocci1,2, Vivianne Presta1, Claudio Ferri3, Josep Redon4, Massimo Volpe5,6. 1. Hypertension Unit, Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, University of Rome Sapienza, Sant'Andrea Hospital, Rome, Italy. 2. IRCCS Neuromed, Pozzilli, IS, Italy. 3. Department of Life, Health and Environmental Sciences, University of L'Aquila, San Salvatore Hospital, L'Aquila, Italy. 4. University of Valencia and CIBER 06/03, Physiopathology of Obesity and Nutrition Institute of Health Carlos III, Madrid, Spain. 5. Hypertension Unit, Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, University of Rome Sapienza, Sant'Andrea Hospital, Rome, Italy. massimo.volpe@uniroma1.it. 6. IRCCS Neuromed, Pozzilli, IS, Italy. massimo.volpe@uniroma1.it.
Abstract
INTRODUCTION: The most recent European guidelines on hypertension redefined office blood pressure (BP) treatment targets according to age strata and cardiovascular (CV) risk profile. AIM: To evaluate proportions of adult outpatients achieving office BP treatment targets recommended by current compared to previous hypertension guidelines. METHODS: We extracted data from medical databases of adult outpatients followed in three excellence centers in hypertension (Rome, Italy; L'Aquila, Italy; Valencia, Spain). Office BP treatment targets were defined according to either 2013 ESH/ESC guidelines (< 140/90 mmHg in non-diabetic individuals aged 18-80 years, < 150/90 mmHg in those aged ≥ 80 years, and < 140/85 mmHg in diabetic individuals), or 2018 ESC/ESH guidelines: (< 130/80 mmHg in individuals aged 18-65 years, < 140/80 mmHg in those aged 65-79 and ≥ 80 years). SCORE risk was assessed in all patients. RESULTS: From an overall sample of 14,229 adult subjects, 4049 (28.5%) resulted normotensive individuals, 3088 (21.7%) were untreated and 7092 (49.8%) treated hypertensive outpatients. Treated hypertensives showed significantly higher ESC score risk (8.3 ± 13.0% vs. 3.9 ± 8.4%; P < 0.001) and lower systolic/diastolic BP (140.6 ± 18.8/83.9 ± 11.5 vs. 148.3 ± 14.2/94.7 ± 10.1 mmHg; P < 0.001) than untreated hypertensives. Compared to previous guidelines, BP control significantly lowered in non-diabetic outpatients (n = 5847) of all age groups [18-65 years: (13.1% vs. 42.9%), 65-79 years (25.8% vs. 42.5%) and ≥ 80 years (29.1% vs. 66.0%); P < 0.001 for all comparisons]; similar reductions were observed in diabetic outpatients (n = 1245) [18-65 years (32.7% vs. 14.8%), 65-79 years (37.3% vs. 24.7%) and ≥ 80 years (47.1% vs. 27.9%); P < 0.001]. CONCLUSIONS: According to the recommended new office BP treatment targets, the proportions of treated uncontrolled hypertensive patients substantially increased. These findings should prompt a tighter application of therapeutic recommendations and, thus, highlight the need for improving hypertension management and control strategies.
INTRODUCTION: The most recent European guidelines on hypertension redefined office blood pressure (BP) treatment targets according to age strata and cardiovascular (CV) risk profile. AIM: To evaluate proportions of adult outpatients achieving office BP treatment targets recommended by current compared to previous hypertension guidelines. METHODS: We extracted data from medical databases of adult outpatients followed in three excellence centers in hypertension (Rome, Italy; L'Aquila, Italy; Valencia, Spain). Office BP treatment targets were defined according to either 2013 ESH/ESC guidelines (< 140/90 mmHg in non-diabetic individuals aged 18-80 years, < 150/90 mmHg in those aged ≥ 80 years, and < 140/85 mmHg in diabetic individuals), or 2018 ESC/ESH guidelines: (< 130/80 mmHg in individuals aged 18-65 years, < 140/80 mmHg in those aged 65-79 and ≥ 80 years). SCORE risk was assessed in all patients. RESULTS: From an overall sample of 14,229 adult subjects, 4049 (28.5%) resulted normotensive individuals, 3088 (21.7%) were untreated and 7092 (49.8%) treated hypertensive outpatients. Treated hypertensives showed significantly higher ESC score risk (8.3 ± 13.0% vs. 3.9 ± 8.4%; P < 0.001) and lower systolic/diastolic BP (140.6 ± 18.8/83.9 ± 11.5 vs. 148.3 ± 14.2/94.7 ± 10.1 mmHg; P < 0.001) than untreated hypertensives. Compared to previous guidelines, BP control significantly lowered in non-diabetic outpatients (n = 5847) of all age groups [18-65 years: (13.1% vs. 42.9%), 65-79 years (25.8% vs. 42.5%) and ≥ 80 years (29.1% vs. 66.0%); P < 0.001 for all comparisons]; similar reductions were observed in diabetic outpatients (n = 1245) [18-65 years (32.7% vs. 14.8%), 65-79 years (37.3% vs. 24.7%) and ≥ 80 years (47.1% vs. 27.9%); P < 0.001]. CONCLUSIONS: According to the recommended new office BP treatment targets, the proportions of treated uncontrolled hypertensivepatients substantially increased. These findings should prompt a tighter application of therapeutic recommendations and, thus, highlight the need for improving hypertension management and control strategies.
Authors: Luis M Ruilope; Gema Ruiz-Hurtado; María G Barderas; Juan J de la Cruz; Alejandro Lucia; Alejandro de la Sierra; Manuel Gorostidi; Ernest Vinyoles; Julián Segura; Jorge Solís; Fernando Arribas; Juan García-Puig; Juan Tamargo; Eoin O'Brien; Massimo Volpe; Paul K Whelton; Bryan Williams; José R Banegas Journal: Hypertension Date: 2019-05-28 Impact factor: 10.190
Authors: Mohammad H Forouzanfar; Patrick Liu; Gregory A Roth; Marie Ng; Stan Biryukov; Laurie Marczak; Lily Alexander; Kara Estep; Kalkidan Hassen Abate; Tomi F Akinyemiju; Raghib Ali; Nelson Alvis-Guzman; Peter Azzopardi; Amitava Banerjee; Till Bärnighausen; Arindam Basu; Tolesa Bekele; Derrick A Bennett; Sibhatu Biadgilign; Ferrán Catalá-López; Valery L Feigin; Joao C Fernandes; Florian Fischer; Alemseged Aregay Gebru; Philimon Gona; Rajeev Gupta; Graeme J Hankey; Jost B Jonas; Suzanne E Judd; Young-Ho Khang; Ardeshir Khosravi; Yun Jin Kim; Ruth W Kimokoti; Yoshihiro Kokubo; Dhaval Kolte; Alan Lopez; Paulo A Lotufo; Reza Malekzadeh; Yohannes Adama Melaku; George A Mensah; Awoke Misganaw; Ali H Mokdad; Andrew E Moran; Haseeb Nawaz; Bruce Neal; Frida Namnyak Ngalesoni; Takayoshi Ohkubo; Farshad Pourmalek; Anwar Rafay; Rajesh Kumar Rai; David Rojas-Rueda; Uchechukwu K Sampson; Itamar S Santos; Monika Sawhney; Aletta E Schutte; Sadaf G Sepanlou; Girma Temam Shifa; Ivy Shiue; Bemnet Amare Tedla; Amanda G Thrift; Marcello Tonelli; Thomas Truelsen; Nikolaos Tsilimparis; Kingsley Nnanna Ukwaja; Olalekan A Uthman; Tommi Vasankari; Narayanaswamy Venketasubramanian; Vasiliy Victorovich Vlassov; Theo Vos; Ronny Westerman; Lijing L Yan; Yuichiro Yano; Naohiro Yonemoto; Maysaa El Sayed Zaki; Christopher J L Murray Journal: JAMA Date: 2017-01-10 Impact factor: 56.272
Authors: Bryan Williams; Giuseppe Mancia; Wilko Spiering; Enrico Agabiti Rosei; Michel Azizi; Michel Burnier; Denis L Clement; Antonio Coca; Giovanni de Simone; Anna Dominiczak; Thomas Kahan; Felix Mahfoud; Josep Redon; Luis Ruilope; Alberto Zanchetti; Mary Kerins; Sverre E Kjeldsen; Reinhold Kreutz; Stephane Laurent; Gregory Y H Lip; Richard McManus; Krzysztof Narkiewicz; Frank Ruschitzka; Roland E Schmieder; Evgeny Shlyakhto; Costas Tsioufis; Victor Aboyans; Ileana Desormais Journal: Eur Heart J Date: 2018-09-01 Impact factor: 29.983
Authors: G Tocci; A Ferrucci; R Pontremoli; C Ferri; E A Rosei; A Morganti; B Trimarco; G Mancia; C Borghi; M Volpe Journal: J Hum Hypertens Date: 2015-02-12 Impact factor: 3.012
Authors: Giuseppe Mancia; Robert Fagard; Krzysztof Narkiewicz; Josep Redon; Alberto Zanchetti; Michael Böhm; Thierry Christiaens; Renata Cifkova; Guy De Backer; Anna Dominiczak; Maurizio Galderisi; Diederick E Grobbee; Tiny Jaarsma; Paulus Kirchhof; Sverre E Kjeldsen; Stéphane Laurent; Athanasios J Manolis; Peter M Nilsson; Luis Miguel Ruilope; Roland E Schmieder; Per Anton Sirnes; Peter Sleight; Margus Viigimaa; Bernard Waeber; Faiez Zannad; Josep Redon; Anna Dominiczak; Krzysztof Narkiewicz; Peter M Nilsson; Michel Burnier; Margus Viigimaa; Ettore Ambrosioni; Mark Caufield; Antonio Coca; Michael Hecht Olsen; Roland E Schmieder; Costas Tsioufis; Philippe van de Borne; Jose Luis Zamorano; Stephan Achenbach; Helmut Baumgartner; Jeroen J Bax; Héctor Bueno; Veronica Dean; Christi Deaton; Cetin Erol; Robert Fagard; Roberto Ferrari; David Hasdai; Arno W Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Patrizio Lancellotti; Ales Linhart; Petros Nihoyannopoulos; Massimo F Piepoli; Piotr Ponikowski; Per Anton Sirnes; Juan Luis Tamargo; Michal Tendera; Adam Torbicki; William Wijns; Stephan Windecker; Denis L Clement; Antonio Coca; Thierry C Gillebert; Michal Tendera; Enrico Agabiti Rosei; Ettore Ambrosioni; Stefan D Anker; Johann Bauersachs; Jana Brguljan Hitij; Mark Caulfield; Marc De Buyzere; Sabina De Geest; Geneviève Anne Derumeaux; Serap Erdine; Csaba Farsang; Christian Funck-Brentano; Vjekoslav Gerc; Giuseppe Germano; Stephan Gielen; Herman Haller; Arno W Hoes; Jens Jordan; Thomas Kahan; Michel Komajda; Dragan Lovic; Heiko Mahrholdt; Michael Hecht Olsen; Jan Ostergren; Gianfranco Parati; Joep Perk; Jorge Polonia; Bogdan A Popescu; Zeljko Reiner; Lars Rydén; Yuriy Sirenko; Alice Stanton; Harry Struijker-Boudier; Costas Tsioufis; Philippe van de Borne; Charalambos Vlachopoulos; Massimo Volpe; David A Wood Journal: Eur Heart J Date: 2013-06-14 Impact factor: 29.983
Authors: Cormac Kennedy; Osama Ali; Richard Farnan; John Stinson; Ahmed Gabr; Mary Hall; Patricia O'Connor; Martina Hennessy; Michael Barry Journal: Ir J Med Sci Date: 2022-01-09 Impact factor: 1.568
Authors: Krzysztof J Filipiak; Miguel Camafort Babkowski; Matteo Cameli; Stefano Carugo; Claudio Ferri; Djamshid B Irisov; Krzysztof Narkiewicz; Ulugbek Nizamov; Leopoldo Pérez de Isla; Anna Tomaszuk-Kazberuk; Andrea Ungar; Aleksandra Gąsecka Journal: Cardiol J Date: 2022-09-19 Impact factor: 3.487